Source: INTERNATIONAL JOURNAL OF PHARMACEUTICS. Unidades: EACH, IF
Subjects: CROMATOGRAFIA, PEPTÍDEOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SANTANA, Hector et al. Screening for stability and compatibility conditions of recombinant human epidermal growth factor for parenteral formulation: effect of pH, buffers, and excipients. INTERNATIONAL JOURNAL OF PHARMACEUTICS, v. 452, n. 1-2, p. 52-62, 2013Tradução . . Disponível em: https://doi.org/10.1016/j.ijpharm.2013.04.054. Acesso em: 26 ago. 2024.APA
Santana, H., Gonzalez, Y., Paez, R., Noda, J., Amarantes, O., Beldarrain, A., et al. (2013). Screening for stability and compatibility conditions of recombinant human epidermal growth factor for parenteral formulation: effect of pH, buffers, and excipients. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 452( 1-2), 52-62. doi:10.1016/j.ijpharm.2013.04.054NLM
Santana H, Gonzalez Y, Paez R, Noda J, Amarantes O, Beldarrain A, Campana PT, Itri R. Screening for stability and compatibility conditions of recombinant human epidermal growth factor for parenteral formulation: effect of pH, buffers, and excipients [Internet]. INTERNATIONAL JOURNAL OF PHARMACEUTICS. 2013 ; 452( 1-2): 52-62.[citado 2024 ago. 26 ] Available from: https://doi.org/10.1016/j.ijpharm.2013.04.054Vancouver
Santana H, Gonzalez Y, Paez R, Noda J, Amarantes O, Beldarrain A, Campana PT, Itri R. Screening for stability and compatibility conditions of recombinant human epidermal growth factor for parenteral formulation: effect of pH, buffers, and excipients [Internet]. INTERNATIONAL JOURNAL OF PHARMACEUTICS. 2013 ; 452( 1-2): 52-62.[citado 2024 ago. 26 ] Available from: https://doi.org/10.1016/j.ijpharm.2013.04.054